76
Participants
Start Date
February 13, 2020
Primary Completion Date
November 7, 2024
Study Completion Date
November 7, 2024
Losmapimod
Patients will receive Losmapimod 15 mg by mouth twice daily for a total of 30 mg daily until 90 days after commercial drug is available post regulatory approval or until the study is discontinued by the Sponsor. The study drug should be taken with food and the date and time of each dose taken should be recorded in the subject diary.
University of Rochester Medical Center, Rochester
Kennedy Krieger Institute, Baltimore
Virginia Commonwealth University, Richmond
University of Florida, Gainesville
Ohio State University, Columbus
Hospital UiP La Fe, Valencia
Washington University School of Medicine, St Louis
University of Kansas Medical Center, Kansas City
University of Utah, Salt Lake City
University of California Los Angeles (UCLA), Los Angeles
University of California Irvine, Irvine
University of Washinton Medical Center, Seattle
University of Massachusetts Memorial Medical Center, Worcester
Ottawa Hospital Research Institute, Ottawa
Montreal Neurological Institute and Hospital, Montreal
CHU de NICE- CHU pasteur2, Nice
Hospital de la Sta Creu i St Pau, Barcelona
Lead Sponsor
Fulcrum Therapeutics
INDUSTRY